Price Controls in Action: Understanding the Rise of the 340B Program
This article was originally published in RPM Report
The health care reform law dramatically expanded the number of entities eligible to purchase drugs via the federally administered 340B program, while simultaneously increasing the size of the mandatory discounts given to covered entities. Manufacturers are understandably frustrated. Rather than hope for elimination of the program, however, they may be better served working within the system to contain its impact.
You may also be interested in...
Long-awaited “mega-guidance” sets boundaries on discount and makes big changes for HIV drugs – and could mean the beginning of the end of the scrutiny of the program. A legislative proposal floated in the context of the “21st Century Cures” bill might move things in a different direction.
The annual hunt for “pay-fors” is on: Congress is looking for offsets to pay for the cost of reversing physician payment cuts under Medicare. One idea would be to allow Medicare Part B to capture the prices of the 340B discount program. Providers who use 340B hate the idea – and manufacturers do too.
Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.